Table 3.
General laboratory findings of COVID-19 patients on admission.
| Median (IQR) |
||||
|---|---|---|---|---|
| ALL (n = 843) | Group A (n = 324) | Group B (n = 358) | Group C (n = 161) | |
| Blood routinea | ||||
| White blood cell count, × 109/L | 5.41 (4.09, 7.17) | 5.60 (4.38, 7.59) | 5.37 (4.06, 7.19) | 4.87 (3.66, 6.35)*# |
| Neutrophil count, × 109/L | 3.66 (2.43, 5.38) | 4.07 (2.59, 6.13) | 3.43 (2.48, 5.44)* | 3.13 (2.14, 4.36)*# |
| Lymphocyte count, × 109/L | 1.00 (0.71, 1.44) | 0.98 (0.68, 1.40) | 0.98 (0.68, 1.40) | 1.08 (0.79, 1.53)*# |
| Platelet count, × 109/L | 209 (164, 272) | 215 (167, 281) | 207 (163, 265) | 193 (151, 255)* |
| Red blood cell count, × 1010/L | 4.10 (3.74, 4.45) | 4.06 (3.76, 4.41) | 4.10 (3.74, 4.49) | 4.16 (3.71, 4.46) |
| Liver functionb | ||||
| Alanine aminotransferase, U/L | 25 (17, 43) | 27 (18, 48) | 24 (16, 40)* | 21 (14, 36)* |
| Aspartate aminotransferase, U/L | 28 (21, 41) | 30 (21, 44) | 28 (21, 41) | 26 (20, 37)* |
| Total bilirubin, μmol/Lc | 10.4 (8.0, 14.2) | 10.7 (8.1, 14.8) | 10.1 (7.6, 14.0) | 10.0 (8.0, 13.0) |
| Direct bilirubin, μmol/L | 3.8 (2.7, 5.1) | 3.9 (2.8, 5.4) | 3.7 (2.6, 5.1) | 3.8 (2.8, 4.9) |
| Albumin, g/L | 36.9 (33.5, 39.8) | 36.7 (33.6, 39.6) | 36.6 (33.0, 39.7) | 37.5 (34.5, 40.3)*# |
| Kidney functiond | ||||
| Creatinine, μmol/L | 61 (50, 73) | 59 (49, 73) | 61 (50, 72) | 62 (51, 74) |
| Blood urea nitrogen, nmol/L | 4.6 (3.6, 6.2) | 4.7 (3.6, 6.0) | 4.6 (3.7, 6.3) | 4.4 (3.4, 6.1) |
| Uric acid, μmol/L | 247 (199, 328) | 235 (196, 319) | 249 (195, 323) | 257 (215, 347)* |
| Estimated glomerular filtration rate, mL/min | 98.7 (88.5, 111.4) | 100.1 (90.2, 111.6) | 97.1 (87.0, 108.3) | 98.9 (88.3, 113.9) |
| Injury of cardiac and skeletal muscle | ||||
| Creatine kinase, U/Le | 62 (39, 107) | 60 (37, 103) | 61 (40, 105) | 64 (43, 118) |
| Creatine kinase-myocardial isoenzyme mb, ng/mLf | 1 (0.6, 1.8) | 0.91 (0.62, 1.56) | 1.03 (0.65, 1.9) | 1 (0.65, 1.83) |
| Lactate dehydrogenase, U/Lg | 270 (211, 371) | 276 (214, 386) | 270 (210, 376) | 251 (202, 347)* |
| Myoglobin, μg/L h | 44.1 (28.8, 85.1) | 42.4 (28.1, 73.0) | 45.6 (29.4, 89.8) | 46.0 (27.5, 79.9) |
| Hypersensitive troponin I,ng/mL i | 0.006 (0.006, 0.017) | 0.006 (0.006, 0.018) | 0.006 (0.006, 0.016) | 0.006 (0.006, 0.017) |
| Arterial Blood Gas Analysisj | ||||
| Blood PH | 7.42 (7.38, 7.45) | 7.42 (7.37, 7.46) | 7.42 (7.38, 7.45) | 7.42 (7.38, 7.45) |
| Arterial oxygen saturation, % | 96 (91, 98) | 95 (90, 98) | 96 (92, 98) | 97 (92, 98) |
| Lactic acid, mmol/L k | 2.2 (1.6, 2.9) | 2.4 (1.8, 3.4) | 2.2 (1.6, 2.8)* | 1.9 (1.4, 2.4)*# |
| Electrolytesl | ||||
| K+, mmol/L | 3.8 (3.4, 4.2) | 3.9 (3.4, 4.3) | 3.8 (3.4, 4.3) | 3.8 (3.4, 4.1) |
| Na+, mmol/L | 139 (136, 142) | 140 (137, 142) | 139 (136, 142) | 140 (136, 142) |
| Cl -, mmol/L m | 105.5 (102.7, 107.8) | 105.3 (102.7, 107.8) | 105.2 (102.5, 107.5) | 106.5 (103.8, 108.4)*# |
| Coagulation functionn | ||||
| Prothrombin time activity, % o | 83.2 (74.9, 91.6) | 82.1 (73.8, 91.4) | 84.0 (76.0, 93.2) | 84.4 (74.1, 92.7) |
| Activated partial thromboplastin time, s | 28.5 (26.3, 31.3) | 27.9 (25.7, 31) | 28.5 (26.3, 31.5) | 29.3 (27.3, 32.2)*# |
| D-dimer, μmol/L | 0.79 (0.41, 2.19) | 0.91 (0.47, 3.55) | 0.78 (0.39, 1.89)* | 0.60 (0.34, 1.30)* |
The total number of patients with available data: a: n(A) = 321, n(B) = 349, n(C) = 157, b: n(A) = 321, n(B) = 347, n(C) = 160; c: n(A) = 320, n(B) = 347, n(C) = 159; d: n(A) = 320, n(B) = 347, n(C) = 160; e: n(A) = 316, n(B) = 340, n(C) = 158; f: n(A) = 254, n(B) = 287, n(C) = 120; g: n(A) = 315, n(B) = 341, n(C) = 158; h: n(A) = 253, n(B) = 285, n(C) = 119; i: n(A) = 254, n(B) = 287, n(C) = 120; j: n(A) = 190, n(B) = 215, n(C) = 86; k: n(A) = 189, n(B) = 215, n(C) = 86; l: n(A) = 322, n(B) = 349, n(C) = 160; m: n(A) = 320, n(B) = 347, n(C) = 160; n: n(A) = 283, n(B) = 307, n(C) = 138; o: n(A) = 283, n(B) = 307, n(C) = 138. *p < 0.05 vs. group A. #p < 0.05 vs. group B.